Company Overview and News
BRUSSELS, Oct 19 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
LBTY DTEGF WHR 500470 LBTYK LILAB KWR DIS DLELY AVOL AWI FOX SPR LBTYB LBTYA IDL SNEJF BKNG TTST TATASTEEL TATLY LILAK SNE MSFT HPQ FOXA DTEGY LILA
(Reuters) - U.S. stocks were set to open higher on Friday as a handful of major U.S. companies posted strong results, helping to relieve concerns about political and growth risks in Europe and Saudi Arabia that drove a 1 percent fall a day earlier.
FOX FOXA DIS
U.S. stock futures ticked higher on Friday as a handful of major U.S. corporations beat results forecasts, offsetting concerns about political and growth risks in Europe, China and Saudi Arabia that drove a 1 percent fall a day earlier.
FOX FOXA DIS
(Reuters) - U.S. stock futures ticked higher on Friday as a handful of major U.S. corporations beat results forecasts, offsetting concerns about political and growth risks in Europe, China and Saudi Arabia that drove a 1 percent fall a day earlier.
FOX FOXA DIS
2018-10-17 investorplace - 1
The last several days have been tough ones for the market, and today aside, people haven’t been keen on stocks to buy. The S&P 500 is down more than 6% from its early October high, and appears to be testing the waters of even lower lows. For some big names like Advanced Micro Devices (NASDAQ:AMD) and FedEx (NYSE:FDX), it has been an even more harrowing phase. AMD shares are off 15% and FedEx has lost 12% for the month.
LRCX IGT AMD COF-D COF-C COF-F CELG DIS CBS FOX JELD COF-P CMCSA OC FDX COF SYF CMI X FOXA
2018-10-16 investorplace - 2
One of the quickest ways to make money in the stock market is through M&A. Acquisition premiums are usually in excess of 20%, so if you own stock in a company and that company gets acquired, you could easily make 20% or more in a day. The potential rewards from takeover stocks are compelling.
FOX REGN AMGN SODA KDP TWX NFLX FIZZ AMRN TWC SNY WMT TGT SFM KR AMZN T KO FOXA DIS
U.S. stock futures pointed to a lower open on Monday, mirroring global stocks, as growing tensions between Western powers and Saudi Arabia added to worries over rising borrowing costs and the impact of tariffs as the earnings season kicks into gear.
FOX AAPL HRS FOXA DIS
NEW YORK (Reuters) - The benchmark S&P 500 index edged lower in choppy trade on Monday as technology stocks were pressured by lingering worries over interest rates and corporate earnings, while gaining Disney shares helped keep the Dow positive.
FOX AAPL HRS FOXA DIS
(Reuters) - A drop in technology stocks on Monday kept pressure on Wall Street and led the Nasdaq lower, but the S&P 500 and Dow Jones Industrial Average eked out slim gains as defensive sectors rose, while traders also pointed to technical support.
FOX 9984 HRS SFTBF FOXA DIS SFTBY
BRUSSELS, Oct 15 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
4091 LBTY DTEGF WHR 500470 LBTYK LILAB DIS DLELY AVOL FOX SPR LBTYB LBTYA IDL CG SNEJF BKNG TTST TATASTEEL TATLY LILAK SNE MSFT HPQ FOXA DTEGY LILA
Walt Disney has offered concessions in an attempt to allay EU antitrust concerns over its US$71.3 billion bid for Twenty-First Century Fox Inc's entertainment assets, the European Commission said on Monday.
FOX FOXA DIS
BRUSSELS (Reuters) - Walt Disney (DIS.N) has offered concessions in an attempt to allay EU antitrust concerns over its $71.3 billion bid for Twenty-First Century Fox Inc’s (FOXA.O) entertainment assets, the European Commission said on Monday.
FOX FOXA DIS
BRUSSELS, Oct 12 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
4091 LBTY HGKGF DTEGF WHR 500470 LBTYK LILAB DIS DLELY AVOL FOX SPR LBTYB LBTYA HGKGY IDL CG SNEJF BKNG TTST TATASTEEL TATLY LILAK SNE MSFT HPQ FOXA DTEGY LILA
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET